Dr. David Louis is Benjamin Castleman Professor of Pathology and chair of Mass General Pathology. His clinical practice and research focuses on the molecular basis of brain tumors and the application of molecular diagnostics to their classification.
- Centers & Specialties
- Neuro-Oncology (Brain)
- Clinical Interests
- Autopsy Pathology
- Frozen Section Pathology
- Medical Education
- MD, SUNY at Stony Brook School of Medicine
- Residency, Albany Medical Center|Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Anatomic Pathology
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Dr. Louis is Benjamin Castleman Professor of Pathology at Harvard Medical School (HMS) and Pathologist-in-Chief at Massachusetts General Hospital (MGH). Under Dr. Louis, the department has become a national leader in molecular diagnostics and pathology informatics, leading to the novel field of computational pathology. Dr. Louis' research focuses on brain tumors and the application of molecular diagnostics to glioma classification, with nearly 300 original articles (h-index = 104). His laboratory was first to demonstrate that molecular approaches could subdivide malignant gliomas biologically and predict the response of malignant gliomas to specific therapies. This work has contributed to worldwide adoption of molecular testing for the management of glioma patients. Dr. Louis has received prestigious awards for his work, including the 2008 Zülch Prize of the Max Planck Society, and has been primary editor for both the 2007 and the 2016 WHO Classification of Tumours of the Central Nervous System. He is chair of the CNS committee for the International Collaboration on Cancer Reporting and is founder of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Dr. Louis was co-chair of the NIH Brain Tumor Progress Review Group and founding chair of the Cancer Biomarkers Study Section at NIH. Dr. Louis recently served as chair of the HMS Pathology Executive Committee, which governs HMS Pathology, and as chair of the MGH Executive Committee on Research, which oversees an approximately $900M research enterprise. Dr. Louis is currently Executive Sponsor of the MGH Center for Innovation in Digital Health.
The 70th meeting of the MGH Scientific Advisory Committee focused on the MGH Research Institute, which was founded in 2015 as an organizational home for the more than 8,500 MGHers in 30 departments, centers and institutes who make up the largest hospital-based research program in the U.S.
The 69th meeting of the MGH Scientific Advisory Committee (SAC), on April 6 and 7, focused on the hospital’s five thematic research centers.
Medical laboratory professionals week – an annual celebration of laboratory professionals and pathologists who play a vital role in every aspect of health care – runs from April 24-30.
Many ‘keen minds’ have worked toward a better understanding of disease to enable improved diagnosis and treatment.
55 Fruit Street
Boston, MA 02114-2696